Melatonin and pro-hypnotic effectiveness of the antidepressant Trazodone: A preliminary evaluation in insomniac mood-disorder patients
| Autor: | Antonio Lucacchini, Laura Betti, B. Pacciardi, Simone Belli, Irene Masala, Federica Luchini, Lionella Palego, Gino Giannaccini, Mauro Mauri, Laura Palagini |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Insomnia medicine.drug_class Clinical Biochemistry Bedtime Melatonin Hypnotic 03 medical and health sciences 0302 clinical medicine Sleep Initiation and Maintenance Disorders Internal medicine medicine Humans Hypnotics and Sedatives Chromatography High Pressure Liquid Morning business.industry Trazodone General Medicine Middle Aged medicine.disease Antidepressive Agents 030227 psychiatry Mood Endocrinology Insomnia Mood disorders Melatonin Trazodone Mood disorders Antidepressant Female business 030217 neurology & neurosurgery medicine.drug |
| Popis: | Objective To preliminary investigate the link between the darkness hormone melatonin (MLT) and the pro-hypnotic effectiveness of the atypical antidepressant Trazodone (TRZ) in a group of mood disorder patients suffering of insomnia. Design and methods The study's design comprised: i) the enrolment of insomniac outpatients, ii) baseline (t 0 ) psychiatric and biochemical examinations; iii) the subsequent patients' introduction into a treatment with TRZ for 3–4 weeks, followed by post-therapy re-evaluations (t 1 ). The MLT function was investigated by t 0 /t 1 ELISA determinations of 6-hydroxy-MLT sulfate (6-OH-MLTs) levels in early-morning urines and HPLC analysis of morning MLT serum amount. Concomitantly, TRZ and its metabolite m -chloro-phenylpiperazine ( m- CPP) were measured by HPLC in serum to monitor patients' compliance/metabolism. Results Seventeen insomniac outpatients, displaying mild symptoms of depression/anxiety resistant to antidepressants, completed TRZ therapy (dose:10–20 mg/day, bedtime). Serum TRZ levels (127 ± 57 ng ml − 1 , mean ± SD) confirmed patients' compliance, while the anxiogenic metabolite m- CPP resulting almost undetectable. Moreover, the 6-OH-MLTs output was found increased at t 1 vs. baseline values (t 1 : 58.4 ± 45.02 ng ml − 1 ; t 0 : 28.6 ± 15.8 ng ml − 1 ; mean ± SD, P P 1 : 48.53 ± 50.70 ng ml − 1 ; t 0 : 49.80 ± 66.53 ng ml − 1 ). Morning MLT in serum slightly diminished at t 1 without reaching the statistical significance, not allowing therefore to define the patients' outcome. Conclusions This initial investigation encourages to explore MLT networks as possible correlates of TRZ pro-hypnotic responses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|